Axi-cel demonstrated significant clinical benefit as a first-line treatment for patients with high-risk large B-cell lymphoma.
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
Response appears to be consistent across histological subtypes.
A multicenter, retrospective study demonstrated higher PFS and OS rates with allogeneic transplant for relapsed/refractory TCL.
The purpose of this study was to evaluate azacitidine in combination with CHOP in a PTCL population enriched for AITL.
The addition of romidepsin to CHOP did not improve PFS over CHOP alone among patients with previously untreated PTCL.